Directors at AOTI (LSE:AOTI) have added to their shareholdings, and a change in a major holding was disclosed this week. On 4 November 2026 the US wound-care company reported share purchases by three senior executives through its employee share purchase plan. A notification of a change in a significant shareholding followed on 16 November. Both come after interim results in late September that showed continued Revenue growth and positive operating cash flow.

What the company does

AOTI, Inc. is a US medical technology company quoted on London's AIM market. It develops and sells TWO2, a topical oxygen therapy for treating chronic wounds such as diabetic foot ulcers. The therapy is used at home, and the company's growth depends heavily on reimbursement from US payers, including Medicare and state Medicaid programmes.

Latest developments

According to the 4 November filing, the chief executive, chief financial officer and chief operating officer each bought around 660 shares at £1.35 per share. The purchases totalled 1,986 shares and were made through the employee share purchase plan. The holdings listed after the deals were 6,789,637 shares (6.38%), 407,121 shares and 1,182,487 shares. The amounts are small, but the filing shows the senior management team continuing to take part in the company's share purchase plan.

The bigger issue for AOTI is reimbursement. On 27 August 2026 the company reported progress on a proposed Medicare Local Coverage Determination (LCD) for topical oxygen therapy. Its interim results said that, once finalised, the LCD is expected to expand the addressable market for TWO2 substantially. Earlier in the year AOTI published a real-world study of the therapy, and in July it described what it called a transformational milestone alongside a trading statement.

Financial picture

AOTI published interim results for the six months to 30 June 2026 on 30 September. Reported revenue rose 10.8% to US$35.3 million. Underlying revenue, which excludes Arizona Medicaid, rose 18.8% to US$31.9 million. EBITDA increased 16.6% to US$3.6 million. Operating Cash Flow was positive at US$0.9 million, compared with an outflow a year earlier, and net Debt was US$6.3 million at the period end. The company said it now held Medicaid provider IDs in 27 US states. No Dividend was referred to.

Sector and index context

AOTI (LSE:AOTI) is one of a group of US-headquartered healthcare businesses that have chosen to list in London and sit in the FTSE AIM All Share Index. Chronic wound care is a large and costly area for US healthcare, and therapies that cut amputations or hospital stays are attractive to payers. In this market, the price and pace of adoption depend heavily on reimbursement decisions.

Key risks

The timing and final wording of the Medicare LCD are uncertain, and a delay or narrower coverage would limit the expected boost to the market. The difference between reported and underlying revenue shows the company's exposure to individual payers such as Arizona Medicaid. AOTI also carries net debt, and it faces competition from other wound-care treatments.

What to watch next

The key catalyst is finalisation of the topical oxygen therapy LCD by Medicare. Investors will also watch for more Medicaid coverage across US states, any trading update around the year-end, and full-year 2026 results. Those results should show whether underlying revenue growth and cash generation have held up.